- Treatment of Hepatitis B Virus Resistant to Lamivudine and Adefovir
-
Kim JW
- KMID: 1767700
- Korean J Gastroenterol.
- 2009 May;53(5):329-330.
- doi: 10.4166/kjg.2009.53.5.329
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Resistance to Adefovir in Patients with Chronic Hepatitis B
-
Ryu SH, Chung YH
- KMID: 938252
- Korean J Hepatol.
- 2006 Dec;12(4):484-492.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Adefovir Dipivoxil in Patients with Decompensated Liver Cirrhosis with Lamivudine Resistance Compared to Patients with Compensated Liver Disease
-
Moon W, Choi MS, Moon YM, Paik SW, Lee JH, Koh KC, Yoo BC, Rhee JC, Shim SG
- KMID: 760590
- Korean J Hepatol.
- 2005 Jun;11(2):125-134.
BACKGROUND/AIMS: Adefovir dipivoxil is effective in patients with lamivudine-resistant hepatitis B virus (HBV). However, little is known about its role in Korean patients with decompensated liver cirrhosis. We retrospectively... -
- CITED
-
- Close
- SHARE
-
- Close
- Antiviral Efficacy of Lamivudine/Adefovir Combination Therapy in Chronic Hepatitis B Patients with Resistance to Lamivudine and Adefovir Consecutively
-
Suh HJ, Park MK, Lee HI, Gwak GY, Koh KC, Paik SW, Yoo BC, Lee JH
- KMID: 1767689
- Korean J Gastroenterol.
- 2009 May;53(5):305-310.
- doi: 10.4166/kjg.2009.53.5.305
BACKGROUND/AIMS: The aim of this study was to elucidate the antiviral efficacy of lamivudine (LMV)-adefovir (ADV) combination therapy in chronic hepatitis B patients who showed resistance to LMV and ADV... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Initial Virologic Response to Adefovir on the Development of Resistance to Adefovir in Lamivudine-resistant Chronic Hepatitis B
-
Kim IH, Kim SH, Kim HC, Shin KD, Kim SW, Lee SO, Lee ST, Kim DG
- KMID: 760736
- Korean J Hepatol.
- 2007 Sep;13(3):349-362.
- doi: 10.3350/kjhep.2007.13.3.349
BACKGROUND/AIMS: Adefovir dipivoxil (ADV) resistance in patients with lamivudine-resistant chronic hepatitis B is not well understood. This study examined the initial virologic response (IVR) to ADV, the rate of... -
- CITED
-
- Close
- SHARE
-
- Close
- Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients
-
Jung HW, Choi MS, Kim KH, Park SH, Yeon KK, Lee JH, Koh KC, Paik SW, Yoo BC
- KMID: 1776814
- Korean J Hepatol.
- 2009 Mar;15(1):52-58.
- doi: 10.3350/kjhep.2009.15.1.52
BACKGROUNDS/AIMS: It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection,... -
- CITED
-
- Close
- SHARE
-
- Close
- High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
-
Chae HB, Kim MJ, Seo EG, Choi YH, Lee HS, Han JH, Yoon SM, Park SM, Youn SJ
- KMID: 1372654
- Korean J Hepatol.
- 2012 Mar;18(1):75-83.
- doi: 10.3350/kjhep.2012.18.1.75
BACKGROUND/AIMS: Newly developed and potent antiviral agents suffer from the problem of drug resistance. Multidrug resistance is a major impediment in the treatment of patients with chronic hepatitis B (CHB).... -
- CITED
-
- Close
- SHARE
-
- Close
- Add on Lamivudine to Adefovir Monotherapy for the Treatment of Lamivudine-resistant Chronic Hepatitis B Patients
-
Cho YJ, Cheong JY, Lee MH, Jeon SJ, Lee YC, Lim SG, Kang CJ, Cho SW
- KMID: 1775862
- Korean J Gastroenterol.
- 2010 Aug;56(2):83-89.
- doi: 10.4166/kjg.2010.56.2.83
BACKGROUND/AIMS: Add on adefovir (ADV) to ongoing lamivudine (LAM) has been recommended as a standard therapy for the treatment of LAM resistance. In the past, switch to ADV monotherapy was... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients
-
Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim SO, Yoo WD, Cho SW
- KMID: 1073330
- Korean J Hepatol.
- 2008 Mar;14(1):58-66.
- doi: 10.3350/kjhep.2008.14.1.58
BACKGROUND/AIMS: Adefovir dipivoxil (adefovir) effectively inhibits both wild-type and lamivudine-resistant hepatitis B virus (HBV) replication. The development of adefovir resistance is both delayed and infrequent compared with lamivudine resistance.... -
- CITED
-
- Close
- SHARE
-
- Close
- The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection
-
Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA
- KMID: 1073302
- Korean J Hepatol.
- 2008 Dec;14(4):503-512.
- doi: 10.3350/kjhep.2008.14.4.503
BACKGROUND/AIMS: Adefovir dipivoxil (ADV) is a nucleotide analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine (LMV)-resistant HBV mutants. The aim of this study was to elucidate the... -
- CITED
-
- Close
- SHARE
-
- Close
- Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
-
Jung YK, Yeon JE, Lee KG, Jung ES, Kim JH, Kim JH, Seo YS, Yim HJ, Um SH, Ryu HS, Byun KS
- KMID: 1792604
- Korean J Hepatol.
- 2011 Dec;17(4):261-267.
- doi: 10.3350/kjhep.2011.17.4.261
BACKGROUND/AIMS: We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared... -
- CITED
-
- Close
- SHARE
-
- Close
